MedTrace Logo

Urokinase Plasminogen Activator Receptor in Abiraterone Treated Patients With Castration Resistant Prostate Cancer

NCT02125617 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 3

Last updated 2026-01-14

No results posted yet for this study

Summary

The purpose of this study is to investigate cleavage products of the urokinase plasminogenactivator receptor (uPAR) in plasma from patients with castration resistant prostate cancer as a predictive marker of response to abiraterone.

Conditions

  • Prostatic Neoplasms

Interventions

DRUG

Abiraterone

1000 mg/day

DRUG

Prednisolone

10 mg/day

Sponsors & Collaborators

  • Janssen-Cilag Ltd.

    collaborator INDUSTRY

  • Kristoffer Rohrberg

    lead OTHER

Principal Investigators

  • Kristoffer S Rohrberg, MD, Phd · Rigshospitalet, Denmark

Eligibility

Min Age
18 Years
Max Age
120 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-01-31
Primary Completion
2016-07-15
Completion
2017-02-14

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02125617 on ClinicalTrials.gov